BMD-001 / BIORCHESTRA - LARVOL DELTA

BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program (PRNewswire) - "BIORCHESTRA...today announced significant progress in its lead drug program – BMD-001. Leveraging a proprietary, IV-formulated brain-targeting RNAi Nanomedicine (BTRiNTM) platform that combines targeted cell delivery capabilities and proprietary RNA chemistries, BMD-001 has achieved significant milestones, including: Broad biodistribution across the brain, demonstrating disease target knockdown and related functional outcomes; and Downstream engagement of epigenetic disease hallmarks, including amyloid β plaques and neurofibrillary tangles."

Clinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease

BMD-001, A BLOOD-BRAIN BARRIER-CROSSING NANOPARTICLE CONTAINING AN ANTISENSE OLIGONUCLEOTIDE AGAINST MIR-485-3P, IMPROVES FUNCTIONAL AND NEURONAL RESPONSES IN PARKINSON'S DISEASE MODELS (ADPD 2023) - "In animal models of PD, we demonstrated target engagement and functional benefit using our novel brain-penetrating nanoparticle-formulated ASO against miR-485-3p. Thus, BMD-001 may be a promising therapeutic candidate for PD patients."

CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • MIR485

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston (PRNewswire) - "Dr. Branden Ryu...was a featured speaker at a plenary session of the RNA Leaders Congress USA in Boston, MA, on October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading compound, BMD-001, derived from studies in non-human primates that demonstrated clearance of both amyloid-β and tau pathological proteins. 'The encouraging results of this experiment are that the intravenous injection of our BDDS™ can deliver drugs broadly in the CNS: to the frontal lobe, thalamus, hypothalamus, striatum and hippocampus, as well as to the spine." He further added: "This experiment confirmed the biodistribution data previously established in the non-human primate but, in addition, the efficacy of BMD-001 established in smaller animal disease models is now confirmed with an efficacy read-out in the non-human primate. This gives us confidence that our brain delivery platform is scalable to the human context...'"

Preclinical • Alzheimer's Disease • CNS Disorders

BMD-001, a nanoparticle containing miR-485-3p antisense oligonucleotide, blocks Alzheimer`s disease progression (AAIC 2022) - No abstract available

Alzheimer's Disease • CNS Disorders • MIR485

BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention (PRNewswire) - “BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation on June 16, 12:00 at BIO International convention, taking place in San Diego, California, between June 13-16, 2022. BIORCEHSTRA's company presentation will cover its lead therapeutic candidate, BMD-001™, a novel RNAi therapeutic for neurodegenerative disease such as AD and ALS, and its proprietary drug delivery system, BDDS™, in the neuroscience category.”

Clinical • Alzheimer's Disease • CNS Disorders

BIORCHESTRA Co., Ltd. (BIO 2022) - "Therefore, BIORCHESTRA’s lead pipeline in Alzheimer’s disease, BMD-001, is an antisense oligonucleotide targeting this pathogenic microRNA encapsulated in a novel proprietary PEG polymer-based drug delivery system (BDDS) to enhance BBB penetration...The company also has an Alzheimer’s disease diagnosis kit, miRStra® that is being investigated in clinical trials in South Korea. In addition to early screening, miRStra® is planned to be utilized in patient selection and monitoring of treatment effect for the biomarker-driven clinical trials."

Alzheimer's Disease • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders • Parkinson's Disease

BMD-001, A NANOPARTICLE CONTAINING MIR-485-3P ANTISENSE OLIGONUCLEOTIDE, BLOCKS ALZHEIMER`SDISEASE PROGRESSION (ADPD 2022) - "Collectively, our findings suggest that miR-485-3p is a useful biomarker as well as a causative factor of the inflammatory pathophysiology of AD. Furthermore, BMD-001 can be a promising candidate for treatment of AD pathology and cognitive decline, establishing a new paradigm in the AD field."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Immunology • Inflammation